
Keywords: راندو; Mepolizumab; Omalizumab; Severe asthma; Exacerbations; Lung function; Tolerability; Crl; credible interval; HRQoL; health related quality of life; ITC; indirect treatment comparison; MEPO; mepolizumab; OCS; oral corticosteroid; OMA; omalizumab; RCT; rando